Glenmark to sell GlaxoSmithKlines asthma drug in Europe
Glenmark has entered into an agreement with Poland-based Celon Pharma for selling a generic version of GSKs inhaler drug in Europe23-10-2015
23-10-2015
Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated October 23, 2015 titled "Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe".23-10-2015
Q2 results on Oct 29, 2015
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 29, 2015, to consider and approve the Company's Unaudited Financial Statements for the Second Quarter/Half Year ended September 30, 2015 (Q2).Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window closed for Directors and other designated employees of the Company...16-10-2015
Updates of Outcome of AGM
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the Minutes of 37th Annual General Meeting (AGM) of the Company held on September 22, 2015.09-10-2015
Updates
Glenmark Pharmaceuticals Ltd has informed BSE that as per the Honourable Court's Order on October 07, 2015, Glenmark has been restrained by a decree of permanent injunction from making, using, selling, distributing, advertising, exporting, offering for sale or dealing in Sitagliptin Phosphate Monohydrate or any other salt of Sitagliptin in any form, alone or in combination with one or more other drugs....08-10-2015
Delhi high court restrains Glenmark from selling anti-diabetes drug
The court bars Glenmark from selling, distributing, marketing or exporting its anti-diabetes drugs Zita and Zita-Met07-10-2015
Disclosure of Voting results of AGM (Clause 35A)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results at the 37th Annual General Meeting (AGM) of the Company held on September 22, 2015, under Clause 35A.22-09-2015
Glenmark to focus on organic growth, not looking at M&A; deals: Glenn Saldanha
Glenmark Pharmaceuticals will focus on organic growth and developing a pipeline of innovative products22-09-2015
Glenmark's Bi-Specific Antibody - GBR 1302 to enter Phase I trials
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 15, 2015 titled "Glenmark's Bi-Specific Antibody - GBR 1302 to enter Phase I trials".15-09-2015
Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets, 50 mg and 200 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 04, 2015 titled "Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets, 50 mg and 200 mg".04-09-2015